EUVIMEDEUVIMED entdecken
Open Access

Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity

Dehshini Ali, Daniel Kudaya, Amaka Ngige, Ariana M Chao iD

Diabetes Obesity and Cardiometabolic CARE · 2026

DOI: 10.2337/doc25-0026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Obesity and Cardiometabolic CARE, 2026. Verfasst von Dehshini Ali und 3 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins School of Public Health, Baltimore, MD. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), such as semaglutide, and dual GLP-1/glucose-dependent insulinotropic polypeptide RAs, such as tirzepatide, are increasingly used for obesity management. However, real-world patterns of discontinuation, reinitiation, and switching among individuals without diabetes remain poorly described. This study describes the real-world patterns of discontinuation and reinitiation of subcutaneous semaglutide and tirzepatide in adults with obesity but without diabetes in an academic medical center. Secondary objectives included evaluating transitions between semaglutide and tirzepatide and switches from these agents to first-generation antiobesity medications (AOMs). RESEARCH DESIGN AND METHODS A retrospective cohort study of adults with obesity but without diabetes who were prescribed semaglutide or tirzepatide was conducted using electronic health record data. Patterns of discontinuation, reinitiation, and switching (change from one agent to another or to a first-generation AOM) were assessed over 12 months. RESULTS Among 9,189 adults initiating subcutaneous semaglutide or tirzepatide, 36.7% of the sample had a prescription that lasted <32 days (mean, 3.6 days), with 82.7% receiving no further prescriptions for AOMs that year. Prescription coverage was 32–179 days and 180–335 days in 27.0% and 17.7% of participants, respectively, with most (72.3% and 89.5%) not having any prescriptions for AOMs thereafter. Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants. Prescriptions to reinitiate or switch to another GLP-1 RA or first-generation AOM were rare. CONCLUSIONS In a real-world academic setting, a substantial proportion of individuals with obesity, but without diabetes, discontinued GLP-1–based treatments.

Autor:innen und Institutionen

  • Johns Hopkins School of Public Health, Baltimore, MD.
  • Johns Hopkins School of Medicine, Baltimore, MD.
  • Johns Hopkins School of Nursing, Baltimore, MD.

ORCID-Profile: Ariana M Chao

Zitieren

APA

Ali, D., Kudaya, D., Ngige, A., & Chao, A. M. (2026). Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity. Diabetes Obesity and Cardiometabolic CARE. https://doi.org/10.2337/doc25-0026

Vancouver

Ali D, Kudaya D, Ngige A, Chao AM. Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity. Diabetes Obesity and Cardiometabolic CARE. 2026. doi:10.2337/doc25-0026

BibTeX
@article{Ali2026,
  author = {Ali, Dehshini and Kudaya, Daniel and Ngige, Amaka and Chao, Ariana M},
  title = {Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity},
  journal = {Diabetes Obesity and Cardiometabolic CARE},
  year = {2026},
  doi = {10.2337/doc25-0026}
}
Kostenlos starten →